Lactobacillus plantarum LPLDL® is a patented probiotic strain that was specifically chosen by scientific screening methods for its positive impact on cholesterol levels.
The aim of this study was to investigate the cholesterol reducing capacity of Lactobacillus plantarum LPLDL®.
Intervention - Single-centre, prospective, randomised, placebo-controlled, parallel-group, double blind human intervention study.
Participants ingested twice daily encapsulated Lactobacillus plantarum LPLDL® (2x109CFU-Colony-Forming Unit) or placebo before breakfast and dinner for 12 weeks.
Participants were split into 2 groups- 'active' and 'placebo', and then classified based on their TC (Total Cholesterol) levels. The classifications were as follows: 1) Low baseline: TC<5mM. 2) Mildy elevated baseline: T C5-5.9mM and 3) High baseline: TC≥6.0mM.
An encapsulated daily dose of Lactobacillus plantarum LPLDL was completely safe and well tolerated and showcased beneficial cholesterol management properties.
The study carried out by Reading university confirmed the safety of L. plantarum LPLDL and further demonstrated its ability to positively impact on cholesterol and blood pressure levels. These results also highlighted that in healthy adults, there is a similar or greater benefit to an individual taking 1.5-2.4g/day of plant sterols/stanols (statins).
Conflict of interest
The authors declare no conflict of interest. This human intervention study was funded by OptiBiotix health PLC and carried out independently by Reading University.